title: Protective effects of vitamins E, B and C and L-carnitine in the prevention of cisplatin-induced ototoxicity in rats.
abstract: OBJECTIVE
  This experimental study aimed to investigate the effects of vitamins E, B and C and L-carnitine in preventing cisplatin-induced ototoxicity.
  
  
  METHODS
  Twenty-five adult, male, Wistar albino rats were randomly allocated to receive intraperitoneal cisplatin either alone or preceded by vitamins B, E or C or L-carnitine. Auditory brainstem response (i.e. hearing thresholds and wave I-IV intervals) and distortion product otoacoustic emissions (i.e. signal-to-noise ratios) were recorded before and 72 hours after cisplatin administration.
  
  
  RESULTS
  The following statistically significant differences were seen: control group pre- vs post-treatment wave I-IV interval values (p < 0.05); control vs vitamin E and B groups' I-IV interval values (p < 0.05); control vs other groups' hearing thresholds; vitamin E vs vitamin B and C and L-carnitine groups' hearing thresholds (p < 0.05); and vitamin B vs vitamin C and L-carnitine groups' hearing thresholds (p < 0.05). Statistically significant decreases were seen when comparing the initial and final signal-to-noise ratios in the control, vitamin B and L-carnitine groups (2000 and 3000 Hz; p < 0.01), and the initial and final signal-to-noise ratios in the control group (at 4000 Hz; p < 0.01).
  
  
  CONCLUSIONS
  Vitamins B, E and C and L-carnitine appear to reduce cisplatin-induced ototoxicity in rats. The use of such additional treatments to decrease cisplatin-induced ototoxicity in humans is still under discussion.
authors.affiliation: First ENT Clinic, Ministry of Health Dişkapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. salicura@yahoo.com
authors.forename: S Alicura
authors.initials: SA
authors.lastname: Tokgöz
authors.forename: E
authors.initials: E
authors.lastname: Vuralkan
authors.forename: N D
authors.initials: ND
authors.lastname: Sonbay
authors.forename: M
authors.initials: M
authors.lastname: Çalişkan
authors.forename: C
authors.initials: C
authors.lastname: Saka
authors.forename: Ö
authors.initials: Ö
authors.lastname: Beşalti
authors.forename: İ
authors.initials: İ
authors.lastname: Akin
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000975:Antioxidants / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002331:Carnitine / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D016057:Evoked Potentials, Auditory, Brain Stem / Q000502:physiology; D034381:Hearing Loss / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D017084:Otoacoustic Emissions, Spontaneous / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D059629:Signal-To-Noise Ratio; D014803:Vitamin B Complex / Q000627:therapeutic use*; D014810:Vitamin E / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000975:Antioxidants; D014803:Vitamin B Complex; D014810:Vitamin E; D001205:Ascorbic Acid; D002945:Cisplatin; D002331:Carnitine